|
Mar 12
|
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
|
|
Mar 11
|
Autolus Therapeutics announces publication in Blood Cancer Journal
|
|
Feb 1
|
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
|
|
Jan 22
|
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
|
|
Jan 11
|
We're Not Very Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Rate
|
|
Jan 10
|
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
|
|
Dec 22
|
Autolus Therapeutics Announces Changes to its Board of Directors
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 10
|
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
|
|
Nov 27
|
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
|
|
Nov 6
|
Autolus Therapeutics announces participation in upcoming conferences
|
|
Nov 6
|
Investors in Autolus Therapeutics (NASDAQ:AUTL) from five years ago are still down 88%, even after 50% gain this past week
|
|
Nov 5
|
Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
|
|
Nov 2
|
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
|
|
Sep 5
|
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
|
|
Aug 7
|
Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Call Transcript
|
|
Apr 27
|
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
|
|
Apr 27
|
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
|
|
Apr 26
|
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
|